Sponsors (12)
The bill improves equity, participant access, and transparency in clinical trials—making results more inclusive and safer—while imposing new compliance, privacy, and cost burdens that may slow or discourage some trials and increase federal and sponsor expenses.
Patients from racial/ethnic minorities, women, seniors, and people with chronic conditions will see clinical trials set measurable enrollment goals and receive targeted outreach, increasing representation and making trial results more relevant and safer for these groups.
Trial participants (especially low-income and mobility-limited patients) will face lower participation barriers through required participant-friendly practices and clearer reimbursement/compensation rules (fewer visits, telemedicine, local labs, out-of-pocket reimbursement guidance), making it easier and cheaper to join trials.
Applying nondiscrimination protections to covered clinical trials strengthens civil-rights safeguards for participants, reducing the risk of exclusion or discriminatory practices in recruitment and conduct.
Small sponsors, academic investigators, and trial operators will face higher administrative, monitoring, reporting, and compliance costs, which may strain budgets or require dedicated staff.
Added compliance burdens and new requirements may slow or cause some sponsors (especially smaller ones) to delay, scale back, or forgo trials, potentially delaying patient access to experimental therapies.
Annual demographic reporting and targeted outreach raise privacy and consent concerns and could be perceived as intrusive or stigmatizing if data handling or targeting is mishandled.
Based on analysis of 5 sections of legislative text.
Conditions NIH protocol approval on detailed demographic recruitment/retention plans and reporting, directs a study of human-subject rules, and funds outreach grants ($10M/yr FY2027–2030).
Introduced December 18, 2025 by Robin L. Kelly · Last progress December 18, 2025
Requires the NIH to make approval of clinical trial protocols conditional on clear, measurable plans to recruit and retain participants across race, ethnicity, age, and sex, plus annual demographic reporting of ongoing trials. Directs a two-year study to update human-subject protections and incentives, mandates a national outreach and education campaign to boost diverse enrollment, and creates a grant program with $10 million authorized per year for FY2027–FY2030 to test community outreach strategies.